The charts of Cytokinetics (CYTK) have caught my attention. Let's take a look at this late-stage bio-pharmaceutical company that is focused on muscle activators and inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining.
More from Investing
Has Thursday's rally made a significant change to the charts?
Drones are set to become a bigger and bigger part of the commercial world and our day-to-day lives.
Let's check and see what clues we can glean from the charts and indicators.
With a high yield of 6.4%, this is an attractive stock for income investors.